Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Reprogramming Fibroblasts into Oligodendrocyte Progenitor Cells May Lead to Cure for Multiple Sclerosis and Cerebral Palsy

By BiotechDaily International staff writers
Posted on 02 May 2013
Working with mouse tissues, investigators have developed a method for converting skin or lung fibroblasts into fully functional oligodendrocytes, the type of cell responsible for myelinating the neurons of the brain and which are lost in myelin disorders such as multiple sclerosis and cerebral palsy.

Cell-based therapies for myelin disorders require technologies to generate functional oligodendrocyte progenitor cells (OPCs). In this regard, investigators at Case Western Reserve School of Medicine (Cleveland, OH, USA) described the direct conversion of mouse embryonic and lung fibroblasts to induced oligodendrocyte progenitor cells (iOPCs) using sets of either three or eight defined transcription factors.

They reported in the April 14, 2013, online edition of the journal Nature Biotechnology that the iOPCs exhibited a bipolar morphology and global gene expression profile consistent with bona fide OPCs. They could be expanded in vitro for at least five passages while retaining the ability to differentiate into multiprocessed oligodendrocytes. When transplanted to hypomyelinated mice, iOPCs were capable of ensheathing host axons and generating compact myelin.

“The myelin repair field has been hampered by an inability to rapidly generate safe and effective sources of functional oligodendrocytes,” said contributing author Dr. Robert Miller, professor of neurosciences at the Case Western Reserve School of Medicine. “The new technique may overcome all of these issues by providing a rapid and streamlined way to directly generate functional myelin producing cells.”

“It is cellular alchemy,” explained senior author Dr. Paul Tesar, assistant professor of genetics and genome sciences at Case Western Reserve School of Medicine. “We are taking a readily accessible and abundant cell and completely switching its identity to become a highly valuable cell for therapy.”

Related Links:

Case Western Reserve School of Medicine




comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.